janssen_latest_logo_on_sign_closer

Janssen says combination Phase III study for immunotherapy Darzalex for multiple myeloma shows significant PFS

pharmafile | June 6, 2016 | News story | Research and Development, Sales and Marketing ASCO, Drig Trial, Janssen, multiple myeloma 

Janssen said combination late stage trials for its immunotherapy drug to treat multiple myeloma showed 61% progression-free survival. 

The company said its Darzalex (daratumumab) also significantly increased the overall response rate in Phase III study. 

Jane Griffiths, company group chairman, Janssen Europe, Middle East and Africa, said: “The findings provide an important insight into the effect daratumumab can have in combination with established regimens, and illustrate the promise of this immunotherapy in earlier lines of treatment.” 

Advertisement

Darzalex was studied in combination with bortezomib (a proteasome inhibitor [PI]) and dexamethasone (a corticosteroid). 

Antonio Palumbo, myeloma unit chief, department of oncology, division of haematology, University of Torino, Italy, said: “We saw clinically meaningful improvements in progression-free survival and overall response rates with daratumumab when combined with standard of care. These compelling Phase III results demonstrate that a regimen built on daratumumab deepens clinical responses and help to underscore its potential for multiple myeloma patients who have been previously treated.” 

Anjali Shukla

Related Content

europe-1395916_640

Sanofi’s Sarclisa gains EU approval for multiple myeloma treatment

Sanofi has received approval from the European Commission for the use of Sarclisa (isatuximab) in …

blood_test

CHMP issues positive opinion for Blenrep combinations in relapsed/refractory multiple myeloma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) …

researchers

Novartis releases new data across oncology and haematology pipelines

Novartis has announced it will present new data at the 2025 American Society of Clinical …

The Gateway to Local Adoption Series

Latest content